Preliminary Program
Session times on those days will not be finalized until the overall program schedule is completed.
Program Tracks (Please click each Track for detailed program information) |
Track 2: Breakthroughs in Cancer Prognostics and Diagnostics |
Track 3: Best Practice on Clinical Oncology
Track 3-1: Head & Neck, Thyroid and CNS Cancers
| Time: May 15, 2019 (Wednesday) Place: Kiri Full Span, 4th Floor |
|
|
Chair |
Dr. Alexander Druy, Head of the Group of Molecular Oncology, D. Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (Moscow), Russia |
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: Comprehensive Analysis of Bone Marrow Involvement and Minimal Residual Disease in Patients with Neuroblastoma by Molecular Markers |
|
14:00-14:25 |
Title: Profile of the Patient with Head and Neck Cancer at the Araguaina - Amazon Cancer Center |
|
14:25-14:50 |
Title: Androgen Receptor is a Potential Novel Therapeutic Target in Glioblastoma Required for Maintaining Cancer Stemness |
|
14:50-15:15 |
Title: Treatment of Early Tongue Cancer with Optical Instrument |
|
15:15-15:30 |
Coffee Break |
| 15:30-15:55 | Title: Long Non-Coding RNA Highly Up-Regulated in Liver Cancer Promotes Epithelial-to-Mesenchymal Transition Process in Oral Squamous Cell Carcinoma Dr. Yuehong Shen, Principle Investigator, Department of Oral and Maxillofacial Surgery, Peking University Shenzhen Hospital, China |
| 15:55-16:20 |
Title: Dose Dependence of Childhood Thyroid Cancer after the Fukushima Daiichi Nuclear Power Plant Accident |
Track 3-2: Gynecologic Cancers and Breast Cancer
|
Time: May 16, 2019 (Thursday) |
|
|
Chair |
Dr. Kiven E. Lukong, Associate Professor, University of Saskatchewan, Canada |
|
09:00-09:05 |
Chair's Introduction |
|
09:05-09:30 |
Title: Genomic Markers of Ovarian Adenocarcinoma and its Relevancy to the Effectiveness of Chemotherapy |
|
09:30-09:55 |
Title: AnnexinA5 Knockdown Could Promote Cell Proliferation and Metastasis in Gastric Cancer |
|
09:55-10:20 |
Title: Breast Tumor Kinase: Brking Bad |
|
10:20-10:45 |
Title: Molecular Breast Cancer Subtypes – Do we Always Need Adjuvant Chemotherapy |
| 10:45-11:10 |
Title: “Silicone Gelbleed Disease” and What is the Cause? |
Track 3-3: Typical Clinical Oncology (Part I)
| Time: May 16, 2019 (Thursday) Place: Takasago, 4th Floor |
|
| Chair | Dr. Cherian Verghese, Assistant Professor, University of Toledo Medical Center, USA |
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: Targeting Renal Cell Carcinoma by Iron-Dependent Cell Death, Ferroptosis |
|
14:00-14:25 |
Title: Recent Advancements in Cholangiocarcinoma Pathophysiology and Management |
|
14:25-14:50 |
Title: Both XELIRI and TegaFIRI Together with Bevacizumab are Effective Regimens for Management of Recurrent or Metastatic Colorectal Cancer |
|
14:50-15:15 |
Title: Correlating the CK20/CK7 Immunostains and Surface Macroscopic Study with Histopathology to Rethink the Nomenclature of Colon Polyps |
|
15:15-15:30 |
Coffee Break |
| 15:30-15:55 | Title: Diagnostic Value of Endoscopic Ultrasonography in Esophageal Cancer-Related Multiple Primary Cancers (MPCs) Dr. Jun Yao, Vice-Chairman, Department of Gastroenterology, Shenzhen People‘s Hospital, China |
| 15:55-16:20 |
Title: Screening for Lung Cancer has Limited Effectiveness Globally and Distracts from much Needed Efforts to Reduce Critical Levels of Worldwide Prevalance of Smoking |
| 16:20-16:45 | Title: Lung Cancer Post Lung Transplantation: A Single Center Experience Dr. Christiaan Tji Gan, Pulmonologist, University Medical Center Groningen (UMCG), The Netherlands |
Track 3-3: Typical Clinical Oncology (Part II)
|
Time: May 17, 2019 (Friday) |
|
|
Chair |
Dr. Jaromir Roubec, Head, Pneumology Department, Hospital Ostrava-Vitkovice, Czech Republic |
|
09:00-09:05 |
Chair's Introduction |
|
09:05-09:30 |
Title: How Should we Optimisize Peri Operative Care in Carcinologic Lung Surgery? |
|
09:30-09:55 |
Title: Combinations of Predictive Markers-The Analysis of Data from the Registry Kelly and Tulung |
|
09:55-10:20 |
Title: Would it be Possible to Reduce Lung Cancer Mortality if we Organise Direct Properly? |
| 10:20-10:45 |
Title: CT Texture Analysis in Oncologic Imaging |
|
10:45-11:10 |
Title: Primary Spinal Intradural Mesenchymal Chondrosarcoma – 16-Years Course of a Disease with Several Local Regrowths Treated with Osteoplastic Laminotomies, Radiotherapy and Chemotherapy |
BIT Group Global Ltd.
Japan-China Business Co., Ltd.
日中商務株式会社
Dr. Vladimir Lazar
Chief Scientific and Operating Officer
WIN Consortium, France
Dr. Ashok Srivastava
Chief Executive Officer & Chief Medical Officer, ClinFomatrix, Cure Pharmaceuticals, Inc, USA
Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2008-2019 BIT Congress Inc.